Silexion Therapeutics (SLXN) Income from Continuing Operations (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Income from Continuing Operations of 2733000.0 for Q1 2026, down 57.52% year-over-year from 6433860.24 in Q1 2025, and up 38.06% quarter-over-quarter from 4412000.0 in Q4 2025.
Silexion Therapeutics (SLXN) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 2733000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 57.52% year-over-year to 2733000.0; the TTM figure through Mar 2026 stood at 12910000.0 (up 23.3% YoY), while the FY2025 annual figure was 11912000.0, up 27.89% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2733000.0, up from 4412000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 809000.0 in Q3 2023, with the low at 11860000.0 in Q3 2024.
- The 4-year median for Income from Continuing Operations is 1811500.0 (2023), against an average of 2960750.0.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 1366.01% in 2024, then surged 72.5% in 2025.
- Silexion Therapeutics' Income from Continuing Operations stood at 1680000.0 in 2023, then slipped by 3.99% to 1747000.0 in 2024, then slumped by 152.55% to 4412000.0 in 2025, then soared by 38.06% to 2733000.0 in 2026.
- Business Quant data shows SLXN's Income from Continuing Operations at 2733000.0 in Q1 2026, 4412000.0 in Q4 2025, and 3262000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | -3.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.55 Mn |
| Mar 31, 2026 | -2.73 Mn |
| Dec 31, 2025 | -4.41 Mn |
| Sep 30, 2025 | -3.26 Mn |
| Jun 30, 2025 | -2.50 Mn |
| Mar 31, 2025 | -1.74 Mn |
| Dec 31, 2024 | -1.75 Mn |
| Sep 30, 2024 | -11.86 Mn |
| Jun 30, 2024 | -1.49 Mn |
| Mar 31, 2024 | -1.42 Mn |
| Dec 31, 2023 | -1.68 Mn |
| Sep 30, 2023 | -809,000.00 |
| Jun 30, 2023 | -1.88 Mn |